Table II.

Response to first-line platinum based regimens and second-line paclitaxel chemotherapy.

Response	No. patients (%) first-line cisplatin	No. of patients (%) second line paclitaxel
Complete response	0 (0)	0 (0)
Partial response	9 (21.4)	4 (9.5)
Stable disease	20 (47.6)	15 (35.7)
Progressive disease	11 (26.2)	21 (50.0)
Not available	2 (4.8)	2 (4.8)
Response rate (%)	21.4	7.1
Disease control rate	69.1	45.2
Median time to progression	5 months	3 months
Discontinuation due to progression	26 (61.9)	33 (78.5)
Discontinuation due to toxicities	7 (16.7)	1 (2.4)